Literature DB >> 15528268

Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype.

Rasmus Jorgensen1, Lene Martini, Thue W Schwartz, Christian E Elling.   

Abstract

To dissect the interaction between beta-arrestin ((beta)arr) and family B G protein-coupled receptors, we constructed fusion proteins between the glucagon-like peptide 1 receptor and (beta)arr2. The fusion constructs had an increase in apparent affinity selectively for glucagon, suggesting that (beta)arr2 interaction locks the receptor in a high-affinity conformation, which can be explored by some, but not all, ligands. The fusion constructs adopted a signaling phenotype governed by the tethered (beta)arr2 with an attenuated G protein-mediated cAMP signal and a higher maximal internalization compared with wild-type receptors. This distinct phenotype of the fusion proteins can not be mimicked by coexpressing wild-type receptor with (beta)arr2. However, when the wild-type receptor was coexpressed with both (beta)arr2 and G protein-coupled receptor kinase 5, a phenotype similar to that observed for the fusion constructs was observed. We conclude that the glucagon-like peptide 1 fusion construct mimics the natural interaction of the receptor with (beta)arr2 with respect to binding peptide ligands, G protein-mediated signaling and internalization, and that this distinct molecular phenotype is reminiscent of that which has previously been characterized for family A G protein-coupled receptors, suggesting similarities in the effect of (beta)arr interaction between family A and B receptors also at the molecular level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528268     DOI: 10.1210/me.2004-0312

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  35 in total

1.  Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Authors:  Karen Coopman; Yan Huang; Neil Johnston; Sophie J Bradley; Graeme F Wilkinson; Gary B Willars
Journal:  J Pharmacol Exp Ther       Date:  2010-05-27       Impact factor: 4.030

Review 2.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

Review 3.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

4.  Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.

Authors:  Brian P Cary; Marlies V Hager; Samuel H Gellman
Journal:  Chembiochem       Date:  2019-09-20       Impact factor: 3.164

5.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

8.  Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.

Authors:  Marlies V Hager; Lachlan Clydesdale; Samuel H Gellman; Patrick M Sexton; Denise Wootten
Journal:  Biochem Pharmacol       Date:  2017-03-29       Impact factor: 5.858

Review 9.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

10.  SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.

Authors:  M E Bradley; M E Bond; J Manini; Z Brown; S J Charlton
Journal:  Br J Pharmacol       Date:  2009-04-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.